Concept Life Sciences (CLS), a leading integrated drug discovery, development, and manufacturing organization backed by Limerston Capital, today announced key strategic appointments and advancements to further strengthen its services for the global pharmaceutical and biotechnology sectors.
CLS is pleased to welcome Professor Luke O’Neill, and Dr. Shane Liddelow to its Scientific Advisory Board (SAB), while Dr. Ian Waddell, who joined the Board of Directors last year, continues to provide invaluable leadership.
The appointments to the SAB reinforce CLS’s position as a leading partner for innovative drug discovery solutions. Professor O’Neill and Dr. Liddelow bring a wealth of expertise across immunology and neuroscience, respectively, enhancing CLS’s ability to meet the evolving needs of the global life sciences industry.
CLS has made major advancements in automated solid-phase peptide synthesis (SPPS) capabilities. Combined with in-house peptide experts, this enables it to accelerate client projects requiring challenging custom peptide synthesis.
In addition, CLS has made a significant investment, amounting to a five-figure sum in GBP, to enhance its capabilities in Automated ADME (Absorption, Distribution, Metabolism, Excretion) systems and the purchase of a Supercritical Fluid Chromatography purification instrument. This strategic investment drives industry-leading assay turnaround times with no minimum volume requirement and strengthens CLS’s ability to provide high-quality, tailored services, particularly for complex drug discovery projects.
These investments further solidify CLS’s standing as a key partner to pharmaceutical and biotech companies, providing comprehensive drug discovery services from early-stage research through to clinical trials.
The news follows CLS’s acquisition of Charnwood Discovery which completed at the end of 2024 and further enhances the company’s integrated drug discovery offer. This underlines the business’s growth strategy, demonstrating its ambitions and further strengthening its ability to accelerate drug candidates to clinic with high success rates and across different modalities.
Discover the latest trends and insights—explore the Business Insights Journal for up-to-date strategies and industry breakthroughs!
